Sensus Healthcare (SRTS) Reports Q2 Loss of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Sensus Healthcare Reports Second Quarter 2016 Results
August 4, 2016 4:05 PM EDTBOCA RATON, Fla., Aug. 4, 2016 /PRNewswire/ --Â Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported its financial results for the second quarter ended June 30, 2016.
Recent Business Highlights
Successfully completed Initial Public Offering on June 2, 2016 raising net proceeds of $10.4 million Expanded sales team to 12 experienced employees during the quarter, with specializations in dermatology and radiation oncology Sold 14 systems during the quarter, increasing worldwide... More